Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T92403
|
||||
Former ID |
TTDR00035
|
||||
Target Name |
Sodium/hydrogen exchanger 3
|
||||
Gene Name |
SLC9A3
|
||||
Synonyms |
NHE-3; Na(+)/H(+) exchanger 3; SLC9A3
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Angina pectoris [ICD9: 413; ICD10: I20] | ||||
Cardiac arrhythmias [ICD9: 427; ICD10: I47-I49] | |||||
Constipation [ICD9: 564; ICD10: K59.0] | |||||
Chronic kidney disease [ICD9: 403, 585.1-585.5, 585.9; ICD10: N18] | |||||
Cheyne-stokes respiration [ICD10: R06.3] | |||||
Heart arrhythmia [ICD10: I47-I49] | |||||
Renal disease [ICD10: N00-N29] | |||||
Function |
Involved in pH regulation to eliminate acids generated by active metabolism or to counter adverse environmental conditions. Major proton extruding system driven by the inward sodium ion chemical gradient. Plays an important role in signal transduction.
|
||||
BioChemical Class |
Monovalent cation:proton antiporter
|
||||
Target Validation |
T92403
|
||||
UniProt ID | |||||
Sequence |
MWGLGARGPDRGLLLALALGGLARAGGVEVEPGGAHGESGGFQVVTFEWAHVQDPYVIAL
WILVASLAKIGFHLSHKVTSVVPESALLIVLGLVLGGIVWAADHIASFTLTPTVFFFYLL PPIVLDAGYFMPNRLFFGNLGTILLYAVVGTVWNAATTGLSLYGVFLSGLMGDLQIGLLD FLLFGSLMAAVDPVAVLAVFEEVHVNEVLFIIVFGESLLNDAVTVVLYNVFESFVALGGD NVTGVDCVKGIVSFFVVSLGGTLVGVVFAFLLSLVTRFTKHVRIIEPGFVFIISYLSYLT SEMLSLSAILAITFCGICCQKYVKANISEQSATTVRYTMKMLASSAETIIFMFLGISAVN PFIWTWNTAFVLLTLVFISVYRAIGVVLQTWLLNRYRMVQLEPIDQVVLSYGGLRGAVAF ALVVLLDGDKVKEKNLFVSTTIIVVFFTVIFQGLTIKPLVQWLKVKRSEHREPRLNEKLH GRAFDHILSAIEDISGQIGHNYLRDKWSHFDRKFLSRVLMRRSAQKSRDRILNVFHELNL KDAISYVAEGERRGSLAFIRSPSTDNVVNVDFTPRSSTVEASVSYLLRENVSAVCLDMQS LEQRRRSIRDAEDMVTHHTLQQYLYKPRQEYKHLYSRHELTPTEDEKQDREIFHRTMRKR LESFKSTKLGLNQNKKAAKLYKRERAQKRRNSSIPNGKLPMESPAQNFTIKEKDLELSDT EEPPNYDEEMSGGIEFLASVTKDTASDSPAGIDNPVFSPDEALDRSLLARLPPWLSPGET VVPSQRARTQIPYSPGTFCRLMPFRLSSKSVDSFLQADGPEERPPAALPESTHM |
||||
Drugs and Mode of Action | |||||
Drug(s) | AVE-0657 | Drug Info | Phase 2 | Cheyne-stokes respiration | [522222] |
AZD1722 | Drug Info | Phase 2 | Renal disease | [524182] | |
AZD1772//RDX5791 | Drug Info | Phase 2 | Chronic kidney disease | [550265] | |
RDX-5791 | Drug Info | Phase 2 | Constipation | [523444] | |
CARIPORIDE | Drug Info | Discontinued in Phase 2 | Angina pectoris | [545749] | |
ENIPORIDE | Drug Info | Discontinued in Phase 2 | Cardiac arrhythmias | [546734] | |
HOE-694 | Drug Info | Terminated | Heart arrhythmia | [534245] | |
Inhibitor | AVE-0657 | Drug Info | [532610] | ||
CARIPORIDE | Drug Info | [534705] | |||
ENIPORIDE | Drug Info | [534705] | |||
HOE-694 | Drug Info | [534413] | |||
N-(3-Methanesulfonyl-4-methoxy-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(3-Methanesulfonyl-4-methyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Bromo-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Chloro-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(4-Cyano-3-methanesulfonyl-benzoyl)-guanidine | Drug Info | [534413] | |||
N-(5-Methanesulfonyl-2-methyl-benzoyl)-guanidine | Drug Info | [534413] | |||
Modulator | AZD1722 | Drug Info | [550792] | ||
AZD1772//RDX5791 | Drug Info | [550792] | |||
RDX-5791 | Drug Info | [550792] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Proximal tubule bicarbonate reclamation | ||||
Protein digestion and absorption | |||||
Bile secretion | |||||
Mineral absorption | |||||
Pathway Interaction Database | Endothelins | ||||
RhoA signaling pathway | |||||
WikiPathways | SIDS Susceptibility Pathways | ||||
References | |||||
Ref 522222 | ClinicalTrials.gov (NCT00614250) Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea. U.S. National Institutes of Health. | ||||
Ref 523444 | ClinicalTrials.gov (NCT01340053) A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C). U.S. National Institutes of Health. | ||||
Ref 524182 | ClinicalTrials.gov (NCT01764854) Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis. U.S. National Institutes of Health. | ||||
Ref 534245 | Effect of Hoe 694, a novel Na(+)-H+ exchange inhibitor, on intracellular pH regulation in the guinea-pig ventricular myocyte. Br J Pharmacol. 1996 Aug;118(8):1905-12. | ||||
Ref 545749 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004531) | ||||
Ref 532610 | Inhibition of central Na(+)/H(+) exchanger type 3 can alleviate sleep apnea in Sprague-Dawley rats. Chin Med J (Engl). 2014;127(1):48-53. | ||||
Ref 534413 | J Med Chem. 1997 Jun 20;40(13):2017-34.(2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.